BridgeBio director granted RSUs and stock options

BridgeBio Pharma director Charles J. Homcy reported equity awards consisting of restricted stock units and stock options.

Rhea-AI Filing Summary

BridgeBio Pharma director Charles J. Homcy reported equity awards consisting of restricted stock units and stock options. He received 3,990 RSUs, each representing a contingent right to one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.

The RSUs and the shares underlying the options vest in full on June 22, 2027, conditioned on his continued service on the board of directors through that date. Following the RSU grant, Homcy directly holds 919,876 shares of BridgeBio common stock, plus 5,277 options expiring on June 21, 2036.

Insider Trade Summary

Grant/Award: 9,267 shares

Grant/Award 2 txns

Insider HOMCY CHARLES J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	$0.00
Grant/Award	Common Stock	3,990	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 contracts (Direct); Common Stock — 919,876 shares (Direct)

Footnotes (3)

1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSUs granted: 3,990 units Options granted: 5,277 options Option exercise price: $68.92 per share +3 more

6 metrics

RSUs granted 3,990 units Restricted stock units granted on June 22, 2026

Options granted 5,277 options Stock Option (Right to Buy) granted on June 22, 2026

Option exercise price $68.92 per share Conversion/exercise price for 5,277 options

Shares after RSU grant 919,876 shares Total common shares directly held after transaction

Option expiration June 21, 2036 Expiration date of 5,277 stock options

Vesting date June 22, 2027 Full vesting for RSUs and underlying option shares

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), contingent right, vesting

4 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 68.9200 and expiration date of 2036-06-21."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

vesting financial

"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did BridgeBio (BBIO) director Charles J. Homcy receive?

Charles J. Homcy received 3,990 restricted stock units (RSUs) and 5,277 stock options. Each RSU is a contingent right to one share of BridgeBio common stock, while the options give him the right to buy shares at a fixed price.

When do Charles J. Homcy’s new BridgeBio (BBIO) RSUs and options vest?

Both the 3,990 RSUs and the 5,277 stock options granted to Charles J. Homcy vest in full on June 22, 2027. Vesting is conditioned on his continued service on BridgeBio’s board of directors through that vesting date.

What is the exercise price of Charles J. Homcy’s new BridgeBio (BBIO) stock options?

The newly granted stock options to Charles J. Homcy have an exercise price of $68.92 per share. These options cover 5,277 shares of BridgeBio common stock and give him the right to buy shares at that fixed price once vested.

How many BridgeBio (BBIO) shares does Charles J. Homcy hold after this Form 4?

After the reported RSU grant, Charles J. Homcy directly holds 919,876 shares of BridgeBio common stock. In addition, he holds 5,277 stock options that are scheduled to vest on June 22, 2027, subject to continued board service.

What does each RSU granted to Charles J. Homcy by BridgeBio (BBIO) represent?

Each RSU granted to Charles J. Homcy represents a contingent right to receive one share of BridgeBio common stock. The RSUs will convert into actual shares only if the vesting condition—continued service on the board through June 22, 2027—is satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMCY CHARLES J

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		A(1)		3,990	A	$0(2)	919,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		(3)	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)